Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease –Associated Kidney Cancer

The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease –associated renal cell carcinoma.

Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news